Bone-building drugs double the risk of esophageal cancer, but the risk is still small

The family of bone-building drugs that includes Fosamax, Actonel and Boniva can double the risk of developing throat cancer, researchers reported Thursday in the latest development in what has become a confusing discussion. Other studies have reported no increase, but even if the newest finding is correct, the risk is still quite small–about two cases per 1,000 people between age 60 and 79 …